Pfizer Inc. (NYSE:PFE) Shares Sold by Keeley Teton Advisors LLC

Keeley Teton Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 30.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,353 shares of the biopharmaceutical company’s stock after selling 5,900 shares during the quarter. Keeley Teton Advisors LLC’s holdings in Pfizer were worth $354,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PSI Advisors LLC grew its position in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in shares of Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares in the last quarter. Lipe & Dalton lifted its position in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 401 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Shares of PFE opened at $22.05 on Thursday. The firm has a market capitalization of $125.06 billion, a price-to-earnings ratio of 15.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The stock’s fifty day moving average is $25.02 and its 200-day moving average is $26.28. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.